Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients
- 21 June 2022
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (6), e0028322
- https://doi.org/10.1128/aac.00283-22
Abstract
Inhaled formulations of amphotericin B are the most widely used antifungal prophylactic agents in lung transplant recipients, yet there are limited data on their safety. We performed a single-center retrospective cohort study of 603 consecutive patients who underwent lung transplantation between 2012 and 2017 and received antifungal prophylaxis with inhaled amphotericin B lipid complex (iABLC) from the day of transplantation until hospital discharge. Of 603 patients, 600 (99.5%) received >= 1 dose of iABLC, and 544 (90.2%) completed the recommended prophylactic course. In total, 4,128 iABLC doses (median, 5; range, 1 to 48 per patient) were administered; 24 patients received >3 months of therapy. Only one (0.2%) patient discontinued therapy due to a drug-attributable adverse event. During the first posttransplant year, 80 (13.3%) patients died (median time to death, 171 days; interquartile range [IQR], 80 to 272 days), and 3,352 (median, 6 per patient) lung biopsies were performed; 414 (68.7%) patients developed biopsy-proven acute cellular rejection. One-year adverse events in our cohort of lung transplant recipients treated with iABLC during transplant hospitalization matched national outcomes for rejection, graft loss, and death. iABLC is a safe and well-tolerated antifungal prophylactic agent in lung transplant recipients.This publication has 22 references indexed in Scilit:
- Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national surveyTransplant Infectious Disease, 2015
- Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantationThe Journal of Heart and Lung Transplantation, 2015
- Epidemiology of Invasive Mold Infections in Lung Transplant RecipientsAmerican Journal of Transplantation, 2014
- The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report—2013; Focus Theme: AgeThe Journal of Heart and Lung Transplantation, 2013
- Activation of Sterol-response Element-binding Proteins (SREBP) in Alveolar Type II Cells Enhances Lipogenesis Causing Pulmonary Lipotoxicity*Online Journal of Public Health Informatics, 2012
- Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)Clinical Infectious Diseases, 2010
- Fungal infections in lung transplant recipientsCurrent Opinion in Pulmonary Medicine, 2008
- A Randomized Controlled Trial of Tacrolimus Versus Cyclosporine After Lung TransplantationThe Journal of Heart and Lung Transplantation, 2007
- Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipientsTransplantation, 2004
- Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003